The pharmaceuticalindustry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms and the gravity of unmet need, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Adenovirus-based medicinal compositions.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
Adenovirus-based medicinal compositions is a key innovation area in pharmaceutical
Adeno-associated virus (AAV) is a DNA virus that can be engineered to deliver DNA to target cells. AAV belongs to the parvovirus family and consists of a single-stranded DNA genome of approximately 4.8 kilobases (kb). Recombinant AAV (rAAV), which lacks viral DNA, is engineered to deliver its DNA payload into the nucleus of a cell. AAV vectors are very stable and can withstand wide fluctuations in temperature and pH with no loss in activity, which makes them an attractive candidate for gene therapies and recombinant vector vaccines.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 30+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of adenovirus-based medicinal compositions.
Key players in adenovirus-based medicinal compositions – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to adenovirus-based medicinal compositions
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|PsiOxus Therapeutics||219||Unlock company profile|
|Targovax||72||Unlock company profile|
|Vascular Biogenics||55||Unlock company profile|
|EpicentRx||54||Unlock company profile|
|DNAtrix||51||Unlock company profile|
|Genemedicine||40||Unlock company profile|
|Hangzhou Converd||29||Unlock company profile|
|Johnson & Johnson||29||Unlock company profile|
|Institut Catala d'Oncologia||21||Unlock company profile|
|Valo Therapeutics||20||Unlock company profile|
|CG Oncology||20||Unlock company profile|
|BioLineRx||18||Unlock company profile|
|TILT Biotherapeutics||17||Unlock company profile|
|Bayer||17||Unlock company profile|
|Ixogen||16||Unlock company profile|
|Beijing Bio-Targeting Therapeutics Technology||13||Unlock company profile|
|Mayo Clinic||12||Unlock company profile|
|Merck & Co||11||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||11||Unlock company profile|
|Momotaro-Gene||11||Unlock company profile|
|Synthetic Biologics||10||Unlock company profile|
|Bionoxx||9||Unlock company profile|
|Hybrid BioSystems||9||Unlock company profile|
|Trieza Therapeutics||8||Unlock company profile|
|Shanghai Yuansong Biotechnology||7||Unlock company profile|
|Memgen||6||Unlock company profile|
|Samyang Holdings||6||Unlock company profile|
|Coastar Therapeutics||6||Unlock company profile|
|AdCure Bio||6||Unlock company profile|
|Cedars-Sinai Health System||6||Unlock company profile|
|Erasmus MC||5||Unlock company profile|
|ORCA Therapeutics||5||Unlock company profile|
|National Cancer Center||5||Unlock company profile|
|UAB Research Foundation||5||Unlock company profile|
|Amgen||5||Unlock company profile|
Source: GlobalData Patent Analytics
PsiOxus Therapeutics is one of the most important players concerning innovation surrounding adenovirus-based therapeutics. The company is largely involved in the cancer immuno-oncology. Its T-SIGn viral vector platform delivers multiple transgene payloads and re-programmes the tumour microenvironment of both primary and metastatic tumours. The platform enables intravenous (IV) delivery of multi-armed genetic payloads to tumours and metastases.
In terms of application diversity, PTC Therapeutics Inc is the top company followed by EpicentRx Inc and AFFiRiS AG. By means of geographic reach, Max-Planck-Gesellschaft holds the top position. Hybrid BioSystems, Ltd and MorphoSys AG are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.